MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.31 6.5

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.23

Max

1.31

Põhinäitajad
By Trading Economics
Sissetulek	-124K -32M
Müük	-372K 1.4M
Aktsiakasum	-0.27
Kasumimarginaal	-2,364.792
Töötajad	161
EBITDA	-13M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+61.29% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-36M 138M
Eelmine avamishind	-5.19
Eelmine sulgemishind	1.31

Uudiste sentiment

By Acuity

20%

80%

37 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. apr 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Nikkei Likely to Fall After U.S.-Iran Peace Talks Break Down -- Market Talk

12. apr 2026, 23:38 UTC

Market Talk

Uudisväärsed sündmused

Oil Climbs as U.S.-Iran Peace Talks Fail, U.S. Navy Starts Blockade of Strait of Hormuz -- Market Talk

12. apr 2026, 23:38 UTC

Market Talk

Australia's Upstream Energy Companies Poised for Consensus Earnings Upgrades -- Market Talk

12. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls as Dollar Strengthens After U.S.-Iran Peace Talks Collapse -- Market Talk

12. apr 2026, 23:31 UTC

Market Talk

A2 Milk's Supply Issues Likely Temporary -- Market Talk

12. apr 2026, 23:09 UTC

Market Talk

Uudisväärsed sündmused

Australian Dollar Hammered by Blockade of Iran Ports -- Market Talk

12. apr 2026, 23:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. apr 2026, 23:06 UTC

Market Talk

Australian Dollar Ripe for a Downward Correction -- Market Talk

12. apr 2026, 22:56 UTC

Uudisväärsed sündmused

Spot Gold Falls 1.9% to $4,658.65 per Ounce

12. apr 2026, 22:54 UTC

Uudisväärsed sündmused

Front-Month Brent Crude Oil Futures Rise 7.6% to $102.42 per Barrel

12. apr 2026, 22:53 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise 8.3% to $104.56 per Barrel, ICE Data Show

12. apr 2026, 22:51 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Climb After U.S.-Iran Peace Talks Break Down

12. apr 2026, 22:50 UTC

Market Talk

Uudisväärsed sündmused

US Dollar Climbs Amid Broad Risk Off Mood In FX Market -- Market Talk

12. apr 2026, 22:37 UTC

Market Talk

Uudisväärsed sündmused

Australian Dollar Under Fire as Middle East Tensions Ratchet Up Again -- Market Talk

11. apr 2026, 08:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

11. apr 2026, 08:20 UTC

Market Talk

Health Care Roundup: Market Talk

11. apr 2026, 08:20 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

11. apr 2026, 00:00 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Big Yachts, Big Bucks -- Barrons.com

10. apr 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10. apr 2026, 21:01 UTC

Tulu

Cango Inc.: Files Annual Report on Form 20-F With SEC

10. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. apr 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10. apr 2026, 20:10 UTC

Omandamised, ülevõtmised, äriostud

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10. apr 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10. apr 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10. apr 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. apr 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10. apr 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

61.29% tõus

12 kuu keskmine prognoos

Keskmine 2 USD 61.29%

Kõrge 2 USD

Madal 2 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

37 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.